María-Victoria Mateos, MD, PhD, shares the results of a subset analysis of TOURMALINE-MM1, which showed that patients with prior exposure to proteasome inhibitors still benefited from ixazomib treatment.
Ixazomib Benefit Persists Despite Prior Therapy in TOURMALINE-MM1 Subset Analysis
Recent Articles
Axicabtagene Ciloleucel Moves to Acute Lymphocytic Leukemia
Axicabtagene ciloleucel, which in October 2017 became the first chimeric antigen receptor (CAR) T-cell therapy approved for the treatment of B-cell lymphoma, showed “promising...
EURO-SKI: Can Patients With CML Stop Tyrosine Kinase Inhibitors?
Treatment with tyrosine kinase inhibitors (TKIs) like imatinib, nilotinib, and dasatinib, has increased the rates of survival and response over previously available therapies for...
Moxetumomab Pasudotox: An Alternative to Chemotherapy in Hairy Cell Leukemia
In a pivotal phase III clinical trial of moxetumomab pasudotox in patients with relapsed/refractory hairy cell leukemia (HCL), three-quarters of participants responded to treatment....
Phase III BFORE Trial: Bosutinib Beats Imatinib for Frontline CML Treatment
Patients with previously untreated chronic myeloid leukemia (CML) who received bosutinib were more likely than those who received imatinib to respond to treatment and...
bb2121: Is CAR T-Cell Therapy Moving to Myeloma?
Chimeric antigen receptor (CAR) T-cell therapies have revolutionized the treatment of acute lymphocytic leukemia and non-Hodgkin lymphoma, and might now be poised to shake...
Current Issue
July 2018 Bonus Mid-Year Edition
This bonus issue features a look at the most recent changes to Maintenance of Certification programs, highlights from recent hematology/oncology meetings, and more.
